If you have a roadmap, why not use it? On Maxiom Group’s blog today, Taylor Burtis asks why more pharma companies aren’t using the Target Product Profile to guide their drug development efforts from the earliest stage. Click here for more. As she points, out, FDA has published a clear guidance document on how to do this. She also mentions a manufacturer who shaved six months and $350,000 off the development timeframe and cost by using the TPP for an NME application for an orphan drug.
Related posts:
- Lean Upstream: Catalyzing Pharma Product Development
- How much more can pharma extract from shop-floor processes and remain competitive? It's time to apply Lean further upstream, says...
- Making Multi-Product Facilities Safe: Why Risk-MaPP Matters
- ISPE’s Risk-MaPP guide aims to bring standards within multi-use facilities in line with the risk- and science-based principles outlined in...
- QbD Classics: Using an Integrated API-Drug Product Approach to Development
- Publshed recently in Pharmaceutical Engineering, Pfizer authors illustrate the use of a "holistic QbD strategy covering both the Active Pharmaceutical...
- Pharmaceutical Quality and Lessons from Toyota: Thomas Friedli on Creating a Continuous Improvement Culture in Pharma
- "You can only achieve long-term savings if you have stable running equipment that enables stable and robust processes. This is...
- Defining the Role of Excipients in a QbD World
- How do we reconcile the demands of the excipient user and manufacturer, who approach QbD in very different ways? Dr....
